In March 2023, the first Dutch patient with Becker muscular dystrophy entered the EDG 5506-201 trial. This is a randomized controlled phase two study in ambulant patients between 18 and 50 years old. EDG 5506-201 is an oral compound that selectively binds to fast muscle myosin to reduce injurious myofiber stress caused by the reduced presence or truncation of dystrophin. Recruitment in the Netherlands is ongoing. For more information, please check this research page or contact us via email@example.com.